GNPX News and Press, Genprex Inc. From 05/06/21

Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise Newly licensed technologies include use of Genprex’s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be resp...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its up...

An Institutional Review Board ("IRB") has granted approval for Genprex's (GNPX) phase 1/2 trial testing its REQORSA immunogene therapy with AstraZeneca’s Tagrisso (osimertinib) in late-stage non-small cell lung cancer.The Acclaim-1 trial will include about 92 patients: Up to ...

Company achieves another milestone relating to its clinical trial strategy Acclaim-1 clinical trial to treat late-stage NSCLC patients whose disease progressed on Tagrisso® Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNP...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell...

Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda ® Company Expects to Recruit Approximately 15 Sites Across the United States Genprex, Inc. (“Genprex” or the “Company”)...

The institutions and companies involved in genetics now lend support to most other areas of life sciences. The contributions include the discovery of genetic markers of disease and gene therapy. The market for genetic testing continues to grow in leaps and bounds, and has gained momentum as th...

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer and diabetes; in addition, Var...

Webinar series will feature a weekly company overview highlighting the Genprex’s gene therapy pipeline in cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute ( ...